Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide

Q: What does this research mean for the field?

The target trial emulation study comparing cardiovascular and cerebrovascular outcomes between semaglutide and tirzepatide by Azzam et al. has important methodological limitations that require clarification. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

顏江河; Guangting Zeng

doi:10.1016/j.jacadv.2026.103402

October 30, 2026JACC AdvancesOpen Access

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide

View Full Paper

Ask AI

Bookmark

Share

Key result

Semaglutide versus tirzepatide comparisons for cardiovascular and cerebrovascular outcomes in a prior target trial emulation study raise methodological concerns requiring further clarification.

Why the study?

Does tirzepatide reduce cardiovascular and cerebrovascular outcomes compared to semaglutide in patients with and without type 2 diabetes?

Key Points

Identify and discuss methodological issues requiring clarification in a target trial emulation comparing cardiovascular and cerebrovascular outcomes between semaglutide and tirzepatide.
Critical analysis and commentary evaluating the methodology of a published target trial emulation by Azzam et al.
Highlights multiple methodological concerns in the published emulation study that warrant additional clarification before drawing firm comparative conclusions between semaglutide and tirzepatide.

Structured PICO

Does tirzepatide reduce cardiovascular and cerebrovascular outcomes compared to semaglutide in patients with and without type 2 diabetes?

P

Population

Patients with type 2 diabetes (n=77,178 at 1 year; n=95,614 at 3 years in matched cohorts) and nondiabetic patients evaluated in a target trial emulation study

I

Intervention

Tirzepatide

C

Comparator

Semaglutide

O

Outcome

Cardiovascular and cerebrovascular outcomes (including incident atrial fibrillation and acute coronary syndrome at 1 and 3 years)hard clinical

Limitations

Inconsistencies in data across sensitivity analyses (divergent risk differences and attenuation ratios for identical incident case endpoints)
Apparent computational error where the 3-year risk difference for acute coronary syndrome (0.09%) falls outside its reported 95% CI (0.10-0.10)
Unexpected sample size pattern after propensity score matching (more matched type 2 diabetes patients at 3 years [n=95,614] than at 1 year [n=77,178])
Mismatch between the stated causal estimand (per-protocol effect) and the actual intention-to-treat analysis without adjustment for nonpersistence or medication switches
Overly heterogeneous exposure definitions and lack of dose regimen differentiation, leading to exposure misclassification

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This commentary highlights critical data inconsistencies, computational errors, and causal inference limitations in a prior target trial emulation study, urging caution when interpreting claims of superior cardiovascular protection with tirzepatide over semaglutide.

Abstract

Methodological ConcernsWe read with great interest the target trial emulation study by Azzam et al 1 comparing cardiovascular and cerebrovascular outcomes between semaglutide and tirzepatide.However, several methodological aspects of this study merit further clarification.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

顏江河 et al. (2026) studied this question. Semaglutide versus tirzepatide comparisons for cardiovascular and cerebrovascular outcomes in a prior target trial emulation study raise methodological concerns requiring further clarification.

synapsesocial.com/papers/6af8f7b3016f830a1d017468 https://doi.org/10.1016/j.jacadv.2026.103402

View Full Paper

Ask AI

Bookmark

Share

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading